Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Velpatasvir in Chronic HCV with Compensated Cirrhosis
NCT04112303Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sofosbuvir + velpatasvir in hepatitis C (HCV), sponsored by Gilead Sciences. Started Oct 2019; status: completed.
02
Drugs
sofosbuvir + velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04112303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04112303.